This technology covers the production of an inactivated trivalent vaccine against <Riemerella anatipestifer> (serotypes 1, 2, and 6), including bacterial culture, inactivation, vaccine formulation, and potency testing. The vaccine provides protective immunity against serotypes 1, 2, and 6, has a shelf life of up to 24 months, effectively reduces losses caused by<R. anatipestifer> infection, decreases antibiotic use, and demonstrates strong potential for commercialization and industrial application.